Biotech Momenta rises on patent suit

Cambridge-based Momenta Pharmaceuticals Inc. shares rose after the biotech said it is suing three generic drug makers for allegedly infringing on two patents it uses to produce its generic version of Lovenox, a popular blood-thinning drug. On Monday, Momenta won US approval to market its generic version after legal battles with French drug maker Sanofi-Aventis. On Wednesday, generic drug firms Watson Pharmaceuticals Inc. and Amphastar Pharmaceuticals said they received approval for their own versions of Lovenox. Momenta said it filed suit against those firms and International Medical Systems.